Literature DB >> 8319977

The genetic effect of engineered vaccine on Pseudomonas aeruginosa infection in mice.

M Nishio1, Y Isobe, H Hatano, S Ohno, K Okuda, N Ishii.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8319977     DOI： 10.1007/bf00188804

Source DB:  PubMed          Journal:  Immunogenetics        ISSN： 0093-7711            Impact factor:   2.846


× No keyword cloud information.
  6 in total

1.  PSEUDOMONAS AERUGINOSA ELASTASE. ISOLATION, CRYSTALLIZATION, AND PRELIMINARY CHARACTERIZATION.

Authors:  K MORIHARA; H TSUZUKI; T OKA; H INOUE; M EBATA
Journal:  J Biol Chem       Date:  1965-08       Impact factor: 5.157

2.  Corneal ulcers caused by protease and elastase from Pseudomonas aeruginosa.

Authors:  K Kawaharajo; C Abe; J Y Homma; M Kawano; E Goto
Journal:  Jpn J Exp Med       Date:  1974-10

3.  Inhibition of human natural killer cell activity by Pseudomonas aeruginosa alkaline protease and elastase.

Authors:  B K Pedersen; A Kharazmi
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

4.  Further studies on the genetic control of murine corneal response to Pseudomonas aeruginosa.

Authors:  R S Berk; L D Hazlett
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

5.  Site-directed mutagenesis of Glu-141 and His-223 in Pseudomonas aeruginosa elastase: catalytic activity, processing, and protective activity of the elastase against Pseudomonas infection.

Authors:  S Kawamoto; Y Shibano; J Fukushima; N Ishii; K Morihara; K Okuda
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

6.  Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.

Authors:  M Connors; A B Kulkarni; P L Collins; C Y Firestone; K L Holmes; H C Morse; B R Murphy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103
  6 in total
  1 in total

1.  Pseudomonas aeruginosa phage lysate as an immunobiological agent. 1. Selection of Pseudomonas aeruginosa clinical strains for phage lysate preparation.

Authors:  G Sekaninová; M Kolárová; J Pillich; J Seménka; H Slavíková; D Kubícková; V Zajícová
Journal:  Folia Microbiol (Praha)       Date:  1999       Impact factor: 2.099
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.